Home/Pipeline/ATR-04

ATR-04

EGFR Inhibitor-Associated Rash

Preclinical / Phase 1Active

Key Facts

Indication
EGFR Inhibitor-Associated Rash
Phase
Preclinical / Phase 1
Status
Active
Company

About Azitra

Azitra is a clinical-stage biopharmaceutical company focused on creating novel therapeutics for skin diseases through microbial and protein engineering. Its core technology platform includes a library of approximately 1,500 unique bacterial strains, augmented by AI/ML and licensed genetic engineering tools, to develop engineered strains of Staphylococcus epidermidis and therapeutic proteins. The company's pipeline targets high-need conditions like Netherton syndrome, EGFR inhibitor-associated rash, and ichthyosis vulgaris, positioning it at the forefront of the emerging live biotherapeutic product field in dermatology.

View full company profile